We reveal that mice with breast cancer driven by mutations upstream of the PI3K/Akt insulin signaling pathway were responsive to dapagliflozin, while those driven by mutations downstream of PI3K/Akt or in pathways with other driver mutations were not. The gene discussed is PIK3CA; the disease is breast cancer.